“An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients with Primary Myelofibrosis Previously Treated with Ruxolitinib”

Type of Cancer
Leukemia

Phase

Division (Location)

Study ID

NCT#

Brief Description
“An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients with Primary Myelofibrosis Previously Treated with Ruxolitinib”

To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.